Literature DB >> 3492994

Effect of ketorolac on Candida albicans ocular infection in rabbits.

E B Fraser-Smith, T R Matthews.   

Abstract

The tendency of corticosteroids to exacerbate ocular infections limits their usefulness. Ketorolac tromethamine, a nonsteroidal anti-inflammatory agent, is under development as an anti-inflammatory ophthalmic drug. In this study, rabbits ocularly infected with Candida albicans were treated topically four times daily with 0.5% ketorolac tromethamine or 0.1% dexamethasone for seven days after infection. Severity of infection was scored using both the Draize scale and Candida colony counts. Seven days after treatment ended, both the overall ocular scores (6/20) and colony count scores (0.5/3) were the same for ketorolac as for the vehicle, indicating no exacerbation of the infection, whereas with dexamethasone these values increased (13/20 and 2.3/3, respectively). During treatment, both ketorolac and dexamethasone reduced conjunctivitis equally (1.5/10) when compared with the vehicle (3.4/10). However, after treatment, conjunctivitis became more severe only in dexamethasone-treated eyes (6/10). Thus, unlike dexamethasone, ketorolac seems to be a drug that can suppress inflammation without exacerbating fungal ocular infection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3492994     DOI: 10.1001/archopht.1987.01060020118042

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  4 in total

1.  In vivo ocular availability of ketorolac following ocular instillations of aqueous, oil, and ointment formulations to normal corneas of rabbits: a technical note.

Authors:  Manjusha Malhotra; Dipak K Majumdar
Journal:  AAPS PharmSciTech       Date:  2005-10-24       Impact factor: 3.246

2.  Aqueous, oil, and ointment formulations of ketorolac: efficacy against prostaglandin E2-induced ocular inflammation and safety: a technical note.

Authors:  Manjusha Malhotra; Dipak K Majumdar
Journal:  AAPS PharmSciTech       Date:  2006       Impact factor: 3.246

Review 3.  Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  M M Buckley; R N Brogden
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

Review 4.  Current perspectives on ophthalmic mycoses.

Authors:  Philip A Thomas
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.